Lycia Therapeutics, Inc. LYCA
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -8.00%
- 1 year
- -8.00%
- Market cap
- 1.44B
- Revenue (ttm)
- 4.43M
- EPS (ttm)
- -1.04
- Shares out
- 52.09M
- YTD return
- -8.00%
- 1-year return
- -8.00%
- Volume
- 195.32K
- Avg volume
- 679.36K
- Open
- 26.70
- Previous close
- 27.18
- Day's range
- 26.98 – 28.03
- 52-week range
- 22.19 – 36.49
2Y -2.40 (-8.00%)
Key statistics
- Enterprise value
- 554.09M
- PEG ratio
- 0.00
- Price / sales
- 324.20
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 124.32M
- Total debt
- 3.16M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 27.33
- 200-day average
- 27.33
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Lycia Therapeutics, Inc.
Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins. Its therapeutic candidate LCA-0061 degrades immunoglobulin E (IgE) for the treatment of allergic diseases, including food allergy. The company also develops LCA-0062, a follow-on program designed to degrade IgE for the treatment of allergic diseases. Additionally, it develops LCA-0321, a candidate designed to selectively degrade TSHR autoantibodies (thyrotropin receptor antibodies, or TRAbs), the pathogenic drivers of Graves' disease. Lycia Therapeutics, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lyciatx.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on LYCA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 26, 2026 | 0 |